574 related articles for article (PubMed ID: 15702813)
21. Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs.
Asero R
Clin Exp Allergy; 2005 Jun; 35(6):713-6. PubMed ID: 15969659
[TBL] [Abstract][Full Text] [Related]
22. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib.
Bavbek S; Celik G; Ozer F; Mungan D; Misirligil Z
J Asthma; 2004 Feb; 41(1):67-75. PubMed ID: 15046380
[TBL] [Abstract][Full Text] [Related]
23. Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis.
Eisen GM; Goldstein JL; Hanna DB; Rublee DA
Aliment Pharmacol Ther; 2005 Mar; 21(5):591-8. PubMed ID: 15740543
[TBL] [Abstract][Full Text] [Related]
24. Angioedema associated with aspirin and rofecoxib.
Marshall LL
Ann Pharmacother; 2005 May; 39(5):944-8. PubMed ID: 15811906
[TBL] [Abstract][Full Text] [Related]
25. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
26. Factors associated with celecoxib and rofecoxib utilization.
Rawson NS; Nourjah P; Grosser SC; Graham DJ
Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796
[TBL] [Abstract][Full Text] [Related]
27. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Maetzel A; Krahn M; Naglie G
Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
[TBL] [Abstract][Full Text] [Related]
28. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization.
Sun SX; Lee KY; Bertram CT; Goldstein JL
Curr Med Res Opin; 2007 Aug; 23(8):1859-66. PubMed ID: 17605893
[TBL] [Abstract][Full Text] [Related]
29. Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
Rabeneck L; Goldstein JL; Vu A; Mayne TJ; Rublee DA
Am J Gastroenterol; 2005 May; 100(5):1043-50. PubMed ID: 15842577
[TBL] [Abstract][Full Text] [Related]
30. Rofecoxib, as a safe alternative for acetyl salicylic acid/nonsteroidal anti-inflammatory drug-intolerant patients.
Bavbek S; Celik G; Pasaoglu G; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(1):57-62. PubMed ID: 16599250
[TBL] [Abstract][Full Text] [Related]
31. Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review.
Perrone MR; Artesani MC; Viola M; Gaeta F; Caringi M; Quaratino D; Romano A
Int Arch Allergy Immunol; 2003 Sep; 132(1):82-6. PubMed ID: 14555862
[TBL] [Abstract][Full Text] [Related]
32. Challenge-based clinical patterns of 223 Spanish patients with nonsteroidal anti-inflammatory-drug-induced-reactions.
Quiralte J; Blanco C; Delgado J; Ortega N; Alcntára M; Castillo R; Anguita JL; Sáenz de San Pedro B; Carrillo T
J Investig Allergol Clin Immunol; 2007; 17(3):182-8. PubMed ID: 17583106
[TBL] [Abstract][Full Text] [Related]
33. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
Florentinus SR; Heerdink ER; de Boer A; van Dijk L; Leufkens HG
Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):437-41. PubMed ID: 15937867
[TBL] [Abstract][Full Text] [Related]
34. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
Zhao SZ; Wentworth C; Burke TA; Makuch RW
Pharmacoepidemiol Drug Saf; 2004 May; 13(5):277-87. PubMed ID: 15133778
[TBL] [Abstract][Full Text] [Related]
35. Are rofecoxib and celecoxib safer NSAIDS?
Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599
[TBL] [Abstract][Full Text] [Related]
36. Intracranial hypertension induced by rofecoxib.
Jacob S; Rajabally YA
Headache; 2005 Jan; 45(1):75-6. PubMed ID: 15663617
[TBL] [Abstract][Full Text] [Related]
37. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.
Goldstein JL; Eisen GM; Agrawal N; Stenson WF; Kent JD; Verburg KM
Aliment Pharmacol Ther; 2004 Sep; 20(5):527-38. PubMed ID: 15339324
[TBL] [Abstract][Full Text] [Related]
38. Aspirin and paracetamol tolerance in patients with nimesulide-induced urticaria.
Asero R
Ann Allergy Asthma Immunol; 1998 Sep; 81(3):237-8. PubMed ID: 9759800
[TBL] [Abstract][Full Text] [Related]
39. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
[TBL] [Abstract][Full Text] [Related]
40. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial.
Pavelka K; Recker DP; Verburg KM
Rheumatology (Oxford); 2003 Oct; 42(10):1207-15. PubMed ID: 12810937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
